News | May 03, 2023
Astec LifeSciences FY23 PAT declines to Rs. 25.6 Cr
The consolidated EBITDA stood at Rs. 89.3 crore in FY23 as compared to Rs. 164.5 crore in the same period last year
The consolidated EBITDA stood at Rs. 89.3 crore in FY23 as compared to Rs. 164.5 crore in the same period last year
The committee voted that FDA should restrict use of LYNPARZA plus abi/pred to these BRCAm mCRPC patients
The strategic appointment is also critical to reinforcing Healthium’s market leadership, corporate governance and deep domain expertis
Brexit had a negative impact on NHS staff shortages and worsened the workforce crisis
UAB Medexy's first order under the Distribution Agreement is for over 5000 units of SHIR and RELIEF&GO products
The partnership will capitalize on the combined capabilities of the two organizations
Clinic will offer Comprehensive Genetic Counselling and Testing Services to empower patients with personalized care
Specialty Chemicals grew 38% YoY for FY23
Revenue from operations at Rs 512.81 crores registered a growth of 17% Y-o-Y for full year FY23
Cooperative agreement with U.S. Government to advance U.S. biopharma industry and ensure pandemic preparedness
Subscribe To Our Newsletter & Stay Updated
